{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17","upperLimit":"1825","value":"1207"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"OS was defined as the time from transplantation to the date of death from any cause or last follow up, measured in days.","dispersionType":"Full Range","groups":[{"description":"Fludarabine 25 mg/m\\^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m\\^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine \\& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \\& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.","id":"OG000","title":"Fludarabine + Melphalan With PBPC"}],"paramType":"MEAN","populationDescription":"Baseline to disease progression, followed up to 5 years post transplant (assess at 100 days, every 3 months for 2 years, then once a year for at least 3 years)","reportingStatus":"POSTED","timeFrame":"Baseline to disease progression, followed up to 5 years post transplant","title":"Average Overall Survival (OS) Length","type":"SECONDARY","unitOfMeasure":"Days"}